112 related articles for article (PubMed ID: 3456492)
41. New bidentates as full inhibitors of enkephalin-degrading enzymes: synthesis and analgesic properties.
Fournié-Zaluski MC; Coulaud A; Bouboutou R; Chaillet P; Devin J; Waksman G; Costentin J; Roques BP
J Med Chem; 1985 Sep; 28(9):1158-69. PubMed ID: 3897541
[TBL] [Abstract][Full Text] [Related]
42. Analgesic effect of actinonin, a new potent inhibitor of multiple enkephalin degrading enzymes.
Hachisu M; Hiranuma T; Murata S; Aoyagi T; Umezawa H
Life Sci; 1987 Jul; 41(2):235-40. PubMed ID: 3298909
[TBL] [Abstract][Full Text] [Related]
43. Discrimination between CCK receptors of guinea-pig and rat brain by cyclic CCK8 analogues.
Durieux C; Pham H; Charpentier B; Roques BP
Biochem Biophys Res Commun; 1988 Aug; 154(3):1301-7. PubMed ID: 3408499
[TBL] [Abstract][Full Text] [Related]
44. The role of bestatin-sensitive aminopeptidase, angiotensin converting enzyme and thiorphan-sensitive "enkephalinase" in the potency of enkephalins in the guinea-pig ileum.
Aoki K; Kajiwara M; Oka T
Jpn J Pharmacol; 1984 Sep; 36(1):59-65. PubMed ID: 6094902
[TBL] [Abstract][Full Text] [Related]
45. ACE-like hydrolysis of gastrin analogs and CCK-8 by fundic mucosal cells of different species with release of the amidated C-terminal dipeptide.
Dubreuil P; Fulcrand P; Rodriguez M; Laur J; Bali JP; Martinez J
Biochim Biophys Acta; 1990 Jun; 1039(2):171-6. PubMed ID: 2163679
[TBL] [Abstract][Full Text] [Related]
46. [Inhibition of the evoked liberation of (Met5)enkephalin from slices of globus pallidus in the presence of thiorphan and bestatin].
Giros B; de la Baume S; Gros C; Schwartz JC
C R Seances Acad Sci III; 1983; 297(13):609-12. PubMed ID: 6424884
[TBL] [Abstract][Full Text] [Related]
47. Changes in turnover of cerebral monoamines following inhibition of enkephalin metabolism by thiorphan and bestatin.
Llorens-Cortes C; Schwartz JC
Eur J Pharmacol; 1984 Sep; 104(3-4):369-74. PubMed ID: 6594244
[TBL] [Abstract][Full Text] [Related]
48. Autoradiographic comparison of the distribution of the neutral endopeptidase "enkephalinase" and of mu and delta opioid receptors in rat brain.
Waksman G; Hamel E; Fournié-Zaluski MC; Roques BP
Proc Natl Acad Sci U S A; 1986 Mar; 83(5):1523-7. PubMed ID: 3006054
[TBL] [Abstract][Full Text] [Related]
49. Electrophysiological studies with new CCK analogs: correlation with binding affinity on B-type receptors.
Böhme GA; Durieux C; Stutzmann JM; Charpentier B; Roques BP; Blanchard JC
Peptides; 1989; 10(2):407-14. PubMed ID: 2755879
[TBL] [Abstract][Full Text] [Related]
50. Carboxylic acids and tetrazoles as isosteric replacements for sulfate in cholecystokinin analogues.
Tilley JW; Danho W; Lovey K; Wagner R; Swistok J; Makofske R; Michalewsky J; Triscari J; Nelson D; Weatherford S
J Med Chem; 1991 Mar; 34(3):1125-36. PubMed ID: 2002454
[TBL] [Abstract][Full Text] [Related]
51. Analysis of the behavioral activity of C- and N-terminal fragments of cholecystokinin octapeptide.
Crawley JN; St-Pierre S; Gaudreau P
J Pharmacol Exp Ther; 1984 Aug; 230(2):438-44. PubMed ID: 6086888
[TBL] [Abstract][Full Text] [Related]
52. Substance P and [Leu]enkephalin are hydrolyzed by an enzyme in pig caudate synaptic membranes that is identical with the endopeptidase of kidney microvilli.
Matsas R; Fulcher IS; Kenny AJ; Turner AJ
Proc Natl Acad Sci U S A; 1983 May; 80(10):3111-5. PubMed ID: 6190172
[TBL] [Abstract][Full Text] [Related]
53. Cholecystokinin octa- and tetrapeptide degradation by synaptic membranes. III. Inactivation of CCK-8 by a phosphoramidon-sensitive endopeptidase.
Deschodt-Lanckman M; Koulischer D; Przedborski S; Lauwereys M
Peptides; 1984; 5(3):649-51. PubMed ID: 6089150
[TBL] [Abstract][Full Text] [Related]
54. Release of proenkephalin-derived opioid peptides from rat striatum in vitro and their rapid degradation.
Patey G; Cupo A; Mazarguil H; Morgat JL; Rossier J
Neuroscience; 1985 Aug; 15(4):1035-44. PubMed ID: 4047398
[TBL] [Abstract][Full Text] [Related]
55. Nociception, enkephalin content and dipeptidyl carboxypeptidase activity in brain of mice treated with exopeptidase inhibitors.
Zhang AZ; Yang HY; Costa E
Neuropharmacology; 1982 Jul; 21(7):625-30. PubMed ID: 6750433
[TBL] [Abstract][Full Text] [Related]
56. Characterisation of two probes for the localisation of enkephalinase in rat brain: [3H]thiorphan and a 125I-labeled monoclonal antibody.
Pollard H; De la Baume S; Bouthenet ML; Schwartz JC; Ronco P; Verroust P
Eur J Pharmacol; 1987 Jan; 133(2):155-64. PubMed ID: 3545855
[TBL] [Abstract][Full Text] [Related]
57. Novel activity of angiotensin-converting enzyme. Hydrolysis of cholecystokinin and gastrin analogues with release of the amidated C-terminal dipeptide.
Dubreuil P; Fulcrand P; Rodriguez M; Fulcrand H; Laur J; Martinez J
Biochem J; 1989 Aug; 262(1):125-30. PubMed ID: 2554881
[TBL] [Abstract][Full Text] [Related]
58. Separate metabolic pathways for Leu-enkephalin and Met-enkephalin-Arg(6)-Phe(7) degradation by rat striatal synaptosomal membranes.
Benuck M; Berg MJ; Marks N
Neurochem Int; 1982; 4(5):389-96. PubMed ID: 20487892
[TBL] [Abstract][Full Text] [Related]
59. Phasic enkephalinergic modulation of nigrostriatal dopamine metabolism: potentiation with enkephalinase inhibitors.
Wood PL
Eur J Pharmacol; 1982 Aug; 82(1-2):119-20. PubMed ID: 6751837
[No Abstract] [Full Text] [Related]
60. Cholecystokinin octa- and tetrapeptide degradation by synaptic membranes. I. Evidence for competition with enkephalins for in vitro common degradation pathways.
Deschodt-Lanckman M; Bui ND
Peptides; 1981; 2 Suppl 2():113-8. PubMed ID: 6283489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
